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Abstract 
Background: Childhood leukaemia survivors treated with haematopoietic stem cell transplantation 
and total body irradiation (HSCT-TBI) have multiple risk factors for reduced bone mineral density 
(BMD) and growth failure; hence BMD assessment must take body size into consideration. This study 
aimed to evaluate size-corrected BMD in leukaemia survivors treated with and without HSCT-
TBI. Methods: Childhood leukaemia survivors treated with HSCT-TBI(n=35), aged 17.3(10.5-20.9) 
years were compared with those treated with chemotherapy-only(n=16) aged 18.5(16.1-20.9) years 
and population references. Outcomes measures included anthropometric measurements and BMD by 
Dual-energy X-ray absorptiometry. BMD was corrected for size as bone mineral apparent density 
(BMAD). Statistical analysis: 1 and 2-sample t-tests, and regression analysis (5% 
significance). Results: HSCT-TBI survivors were lighter, shorter with reduced spinal heights 
compared with chemotherapy-only subjects and population references. Compared with population 
references, HSCT-TBI survivors showed lower BMD-SDS (p=0.008), but no difference in BMAD-
SDS, and chemotherapy-only survivors showed no differences in neither BMD-SDS nor BMAD-SDS. 
All HSCT-TBI participants with BMD-SDS <-2 had BMAD SDS >-2. BMAD-SDS was negatively 
associated with age (r=-0.38,p=0.029) in HSCT-TBI survivors. Conclusions: Size-corrected BMD are 
normal in HSCT-TBI survivors in young adulthood, but may reduce overtime. BMD measurements 
should be corrected for size in these patients to be clinically meaningful.  
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Introduction  
Childhood leukaemia with poor prognostic factors are treated with haematopoietic stem cell 
transplantation (HSCT) after conditioning which may include cytotoxic drugs, monoclonal antibodies 
and total body irradiation (TBI). Previous studies showed that HSCT survivors have a 71% 15-year 
cumulative incidence for developing any chronic health problems. [1]  Endocrine late effects such as 
growth hormone deficiency (GHD), hypogonadism and hypothyroidism are common in childhood 
HSCT survivors especially those who received TBI. [2][3]  Reduced bone mineral density (BMD) has 
also been reported. [4][5][6][7] HSCT-TBI survivors have multiple risk factors that may contribute to 
reduced BMD such as endocrine dysfunction, abnormal body composition including reduction in lean 
mass, nutritional compromise, steroid treatment and sedentary lifestyle.  
Dual-energy X-ray absorptiometry (DXA) scanning is the current recommended method for the 
assessment of bone mineral content (BMC) and BMD in children and adolescents with increased 
fracture risk. The International Society for Clinical Densitometry (ISCD) guidelines recommend that 
in the absence of vertebral compression fracture, the diagnosis of osteoporosis is indicated by the 
presence of both a clinically significant fracture history and BMD Z-score ≤ -2. [8] However, the 
BMD output from DXA scanning is given as an areal bone density, i.e. the ratio of BMC to projected  
bone area g/cm2 (areal BMD). It does not account for the depth of the bone which is a three-
dimensional structure (volumetric BMD). [9] Therefore, smaller bones of the same volumetric density 
will have an apparently lower areal BMD than larger ones, as such, individuals with short stature and 
smaller bones will be over-reported with reduced BMD. [10] In addition, the ISCD guidelines have 
not only emphasised the need for size-correction in children with short stature, but also adjustment for 
soft-tissue measurements in the presence of malnutrition and skeletal muscle deficits. [11]  This is  
particularly relevant to children with chronic diseases, such as in the case of HSCT-TBI survivors, 
where short stature [12] and reduced lean muscle mass [13] are common as a result of GHD, 
hypogonadism, hypothyroidism, steroid therapy and/or poor nutrition.  
National reference data for size-corrected BMD adjusted for age, gender and ethnicity have recently 
become available for children and young adults in the UK. [14] This study primarily aimed to 
compare size-adjustment volumetric BMD in childhood leukaemia survivors treated with and without 
HSCT-TBI with population references. The secondary aim is to investigate risk factors associated 
with size-adjusted BMD in leukaemia survivors treated with HSCT-TBI. 
Method  
Approval for this study was granted by the local Research Ethics Committee (reference number: 
10/H0102/67, 06/Q2001/151, 06/Q2002/89). Participants and, where relevant, their parents gave 
informed written consent or assent prior to participation in the study.  
Subjects and recruitment 
Survivors of childhood leukaemia treated with either chemotherapy alone or with HSCT-TBI under 
the paediatric or transition long term follow up clinics at the Bristol Royal Hospital for Children, 
United Kingdom (U.K.) from 2007-2012 who were 2 or more years after the completion of all 
oncological treatment and had undergone DXA scanning before the age of 21 years were identified 
from the patient databases. All HSCT-TBI survivors were under regular endocrine surveillance as per 
national standards.[15] Patients diagnosed with endocrine disorders such as growth, thyroid, sex 
hormone deficiencies were on appropriate replacement therapies. None were receiving glucocorticoid 
treatment. Exclusion criteria included active malignancy, untreated chronic diseases and pregnancy at 
the time of DXA scanning. Pregnancy in all females was ruled out by patient history and /or a urine 
pregnancy test if applicable on the day of the scan. Comparison was made against U.K. bone density 
reference data measured by DXA adjusted for age, sex and body size from 3598 male and female 
subjects aged between 4-21 years from 7 paediatric centres. [14]  
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Patient characteristics 
Demographic data including age at the time of scanning, ethnicity, fracture history, family history of 
metabolic bone diseases, age at leukaemia diagnosis, and time elapse since completion of treatment. 
Treatment protocols, dosages and type of steroids, and duration of time from the last dose of steroids 
to DXA scanning were obtained from medical records and treatment summaries for all subjects. 
Different type of steroids taken were converted to equivalent strengths of hydrocortisone  
(Dexamethasone: Prednisolone: methylprednisolone: Hydrocortisone = 0.75:4:5:20) and summed to 
calculate the total dose.  
 
In survivors who were also treated with HSCT-TBI, information was also collected on the age at 
HSCT-TBI, conditioning Chemotherapy, TBI dose and fractionation, additional radiotherapy such as 
cranial and/or testicular irradiation, history of graft versus host disease (GVHD) and other long term 
complications associated with HSCT-TBI. 
Anthropometry and pubertal staging  
All participants underwent clinical examination and anthropometric measurements at the time of 
scanning. Weight was measured to the nearest 0.1 kg on digital scales (Seca®, Hamburg, Germany) in 
light clothing without shoes, and height using a Harpenden® stadiometer (Holtain, Crymych, UK). 
Both outcomes were converted to Standard Deviation Scores (SDS) by Coles’ method using the 1990 
UK childhood growth reference data. [16]  Pubertal assessment was scored according to Tanner stages 
by a paediatric endocrinologist. 
DXA measurements  
All participants underwent DXA scanning (Lunar Prodigy® narrow fan beam Scanner, GE Lunar, 
Madison, WI) supported by the software, “enENCORE” version 13.4 (GE Health Care). The DXA 
outputs needed for this study included bone mineral content (BMC), projected vertebral area of 
Lumbar vertebrae L1-L4, total fat mass and total lean body mass (LBM).  
Bone mineral apparent density (BMAD) was calculated according to an adapted Carter methodology: 
[14][17]  
Lumbar spine BMAD (g/cm3) = (BMC1+BMC2+BMC3+BMC4) / (V1+V2+V3+V4) 
where Vn is the volume of the nth individual vertebra calculated as the posterior-anterior nth vertebral 
area to the power of 1.5 and BMCn is the bone mineral content of the nth vertebrae.   
SDS-scores for BMD and BMAD, were calculated according to Coles method, using UK sex, age and 
ethnic- specific reference data for bone mineral density by Crabtree et al. [14]  
Lean body mass (LBM) SDS was calculated from population references as previously described. [18]  
Statistical Analysis 
Numeric data of patient characteristics were reported as median values (ranges) and SDS of each 
group were reported as mean values with 95% confidence intervals (CI). The SDS scores of BMD, 
BMAD and LBM of the HSCT-TBI and chemotherapy-only leukaemia survivors were compared with 
population reference using a 1-sample t-test as mean equals zero. A 2 sample t-test was used to 
compare the differences of the various parameters between the survivors treated with and without 
HSCT-TBI, and also between HSCT-TBI survivors with or without endocrinopathies. The 
associations between BMAD-SDS and potential risk factors including age of primary diagnosis and 
HSCT-TBI, time post HSCT-TBI, age of DXA scan, gender, presence of endocrinopathies, and lean 
mass were explored by univariate and multivariate regression analysis.  A 5% level of significance 
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was used for all tests. All analyses were performed using statistical software, IBM SPSS Statistics for 
Windows, Version 23.0 (Armonk, NY: IBM Corp 2015). 
Results 
Demographics  
A total of 49 childhood leukaemia survivors who have had one or more DXA scans before the age of 
21 years were identified, which included 33 (18 Males) treated with HSCT-TBI and 16 (5 Males) with 
chemotherapy-only. Results of the first DXA scan was used in patients who had more than 1 scan.   
At the time of DXA scanning, HSCT-TBI survivors were of median age 17.3 (10.5-20.9) years and 
chemotherapy-only survivors 18.5 (16.1-20.9) years. In terms of pubertal staging, 22 (63%) in the 
HSCT-TBI and all (100%) in the chemotherapy-only groups were in Tanner stage 5 (table 1). All 
participants in both groups were White Caucasian. 
The HSCT-TBI survivors included subjects with primary diagnosis of Acute lymphoblastic leukaemia 
(ALL) (n=28) and Acute myeloid leukaemia (AML) (n=5). All subjects in the chemotherapy-only 
group had ALL.  The primary diagnosis of leukaemia was made at 3.8 (0.85-15.0) years and 5.6 (1.6-
14.1) years of age in the HSCT-TBI survivors and chemotherapy-only survivors respectively.  All 
subjects were treated according to contemporaneous UK national paediatric leukaemia at the time of 
their diagnosis including primary protocols UKALL11, UKALL 97/99, UKALL2003 for ALL, 
[19][20][21] AML10, AML12 for AML; [22][23] and relapse protocols R1, R2 and R3  for ALL. [24] 
[25] [26] Protocols for ALL consisted of complex regimens of high but variable doses of steroids with 
prednisolone and /or dexamethasone, [19][20][21][24][25][26] 
In the HSCT-TBI group, HSCT-TBI took place at 7.6 (2.4-16.6) years of age, and the time post 
HSCT-TBI was 9.1 (2.3-16.6) years at the time of the study. All patients received TBI (total from 10-
14.4 Gy, single faction n=5, 6 fractions n=1, 8 fractions n=27) and 11 patients were also treated with 
additional cranial irradiation. The total dose of steroids given were lower in the HSCT-TBI than 
chemotherapy-only group (p=0.003). There was no statistical difference in the time from last steroid 
to DXA between the HSCT and chemotherapy only group  (p=0.9). 
Endocrine dysfunction  
Endocrinopathies were present in the HSCT-TBI participants only: GHD (n=26, 78%), 
hypothyroidism (n=17, 52%), and hypogonadism (n=20, 61%, 9 Males). All patients were on 
appropriate hormone replacement at the time of the DEXA scan. GVHD had been previously 
diagnosed in 12 patients but no patients in either groups were on corticosteroids or 
immunosuppressant treatment at the time of DXA scanning. Second tumours had been reported in 2 
HSCT-TBI survivors including 1 with meningioma and 1 with paraspinal rhabdoid tumour. 
Fracture History 
Bone-related history and fractures among the HSCT-TBI participants included  1 subject with 
vertebral fracture, 1 with avascular necrosis of the hip during primary treatment, 1 with incidental 
finding of aneurysmal bone cyst and 1 with osteoid osteoma. In the chemotherapy-only group, 1 
patient had avascular necrosis of the hip at primary treatment and 2 subjects had histories of 
accidental long bone fractures due to trauma that occurred after completion of leukaemia treatment. 
There was no recorded family history of metabolic bone diseases in either groups. Any subjects with 
low vitamin D were on replacement.  
Anthropometry and body composition outcomes 
HSCT-TBI survivors were significantly shorter (p<0.001) and lighter (p=0.02) compared with the 
chemotherapy-only controls and population reference ranges (table 1).  Sitting height was available in 
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28 HSCT-TBI and 16 chemotherapy-only patients. HSCT-TBI survivors had reduced sitting height 
compared with chemotherapy-only subjects (p<0.001) and population references (p<0.001). 
Chemotherapy-only subjects showed a trend towards reduced sitting height although not statistically 
significant (p=0.06). HSCT-TBI survivors showed significant reduction in lean mass for height SDS 
compared with chemotherapy-only (p<0.001) and population references (p<0.001).  
BMD and BMAD  
HSCT-TBI survivors demonstrated significantly lower BMD-SDS (p=0.008), but no differences in 
BMAD-SDS (p=0.25) in comparison to population references. The chemotherapy-only survivors were 
not different to population references in terms of BMD-SDS (p=0.7) and BMAD-SDS (p=0.93). (table 
1, figure 1) There were no differences in BMD-SDS and BMAD-SDS between the HSCT-TBI and 
chemotherapy-only group. In the HSCT-TBI group, 2 patients with BMD-SDS of <-2 had BMAD-
SDS >-2 (figure 2). Outcomes were unchanged when the analysis were repeated comparing all post-
pubertal (Tanner stage 5) subjects only (table 1)  
HSCT-TBI subjects with a primary diagnosis of ALL compared with AML showed no statistical 
differences in BMD-SDS [-0.56 (-0.91, -0.22) vs -0.29 (-2.55, 1.97), p=0.59] or BMAD-SDS [0.11 (-
0.26, 0.47) vs 0.68 (-0.59, 1.97), p=0.22]. Further analysis excluding AML subjects in the HSCT-TBI 
group showed the same findings with lower BMD-SDS but no statistical differences in BMAS-SDS 
compared with population references or the chemotherapy-only controls (table 1).    
 
Factors associated with BMAD-SDS  
Univariate regression analysis showed that BMAD-SDS was negatively associated with age at DXA 
scan (r=-0.38, p=0.029) in the HSCT-TBI survivors (figure 3), whereas no significant relationship 
was shown in the chemotherapy-only subjects (r=0.4, p=0.14). No significance associations were 
demonstrated between BMAD-SDS with age at primary diagnosis or HSCT-TBI, time post HSCT-
TBI, sitting height-SDS or lean mass-SDS. (table 2)  
There was no difference in BMAD-SDS in HSCT-TBI survivors between genders, those who were 
treated with or without additional cranial irradiation, with history of GVHD post HSCT-TBI, and 
those with or without GHD, hypothyroidism or gonadal failure. (table 2). In addition, no associations 
were noted between BMD-SDS and the duration of time from last steroid or total dose in neither 
groups (table 2).  
Multi-regression analysis did not show any differences in the relationship between BMAD-SDS and 
the above risk factors.  
Discussion  
This is the first study to report size-corrected BMD measurements from childhood leukaemia 
survivors treated with and without HSCT-TBI in the U.K. using the recently published national 
reference ranges which are size, gender and ethnically corrected. [14]  Current international guidelines 
emphasise the importance of size correction in BMD measurements for the assessment of fracture risk 
in children and adolescents, especially in those with chronic health problems. [27] A number of 
previous studies have investigated BMD in childhood HSCT survivors, [4][5][6][7] but data on size-
corrected BMD is limited.  
Ruble et al investigated size-corrected BMD in childhood HSCT survivors by DXA and converted 
areal BMD to volumetric BMD according to Kroger et al which assumes the bone is shaped 
cylindrically. [28][29] In our study, BMAD was calculated as per Carter el al which assumes vertebral 
bodies have a cuboidal configuration [17] as this was the method used in the UK reference data. [14]  
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Both are validated methods for BMAD calculations, but neither account for the exact shape of lumbar 
vertebrae. [17][29] Alternative methods such as, quantitative Computed Tomography (QCT) enables 
measurement of true volumetric BMD and measures cortical and trabecular BMD separately. [7] 
Mostoufi-Moab et al reported a reduction in trabecular volumetric BMD of the left tibia on QCT in 
HSCT survivors compared with their population references. [30] Their outcomes, in contrast to our 
study, where HSCT survivors showed no differences in BMAD in comparison to reference 
population, may be due to discrepancies in patients’ characteristics, anatomical site of measurement 
and techniques used. Our cohort compared with Mostoufi-Moab et al included a lower percentage of 
patients with a history of GVHD, and all our patients compared with 50% of their patients with GHD 
were on growth hormone treatment. Previous studies have shown that BMD outcomes between QCT 
and DXA are not equivalent in both children and adults. [31][32] Krase et al reported discrepant 
results between QCT and DEXA in childhood cancer survivors particularly non-white patients, and 
did not show QCT to be more strongly associated with history of fractures than DEXA. [31] There is 
paucity of reference data for QCT in children and adolescents, and established international 
definitions for reduced BMD including osteoporosis may not be applicable in the interpretation of 
QCT outcomes.  
The severity of low BMD can be over-reported when BMD is not corrected for size. In our study, all 
HSCT-TBI survivors with areal BMD-SDS <-2 had BMAD-SDS >-2.  Ruble et al reported 2% of 
their cohort with osteoporosis based on areal BMD, but none using volumetric BMD [28]. However, 
their study defined osteoporosis according to the WHO criteria which primarily refers to post-
menopausal women and do not related to children and young persons with osteoporosis.  
The latest ISCD guidelines advised that the diagnosis of osteoporosis in children and adolescents 
should not be based on densitometric criteria alone. The finding of one or more vertebral compression 
fractures is indicative of osteoporosis. In the absence of vertebral compression fractures, the diagnosis 
of osteoporosis is indicated by the presence of both a clinically significant fracture history and BMD 
Z-score ≤ -2.0. A clinically significant fracture history is one or more of the following: 1) two or more 
long bone fractures by age 10 years; 2) three or more long bone fractures at any age up to age 19 
years. [8] Detailed fracture histories reported vertebral fracture in 1 patient in the HSCT-TBI group 
and 2 subjects from the chemotherapy group reported long bone fractures from trauma. Although 
individuals are likely to recall significant history of fractures, vertebral compression fractures are 
commonly asymptomatic and often under recognised during or after treatment in leukaemia patients. 
[33] Disproportionate loss of spinal height in HSCT especially those on growth hormone replacement 
are commonly assumed to result from poorer growth responses in the vertebral growth plates post 
irradiation. [33] Unrecognised vertebral compression fracture, which can lead to over 20% height 
loss, may also contribute to spinal height loss in some patients, but data in this aspect are lacking. 
Meta-analyses have shown that lean body mass exerts a stronger effect than fat mass on BMD [34] 
secondary to mechanical loading and biochemical usage on bone development. It has been proposed 
that bone strength is influenced by mechanical muscle force and hormone factors, and the force that 
the muscles exert against bone is influenced by the amount of body mass the muscle and bones 
support, resulting in a positive relationship between muscle mass and bones. [35] The latest ISCD 
guidelines emphasised the need for adjustment in soft-tissue measurements in those with skeletal 
muscle deficits. [8] Loss of lean mass in HSCT-TBI survivors may be associated with treatment 
toxicity linked to TBI, chemotherapy and additional steroids for treatment of GVHD. We have 
demonstrated reduction in lean mass in HSCT-TBI survivors consistent with that previously 
reported,[13] but we have not found a relationship between lean mass and BMAD in our study. This 
may be due to the limited duration of follow up post HSCT-TBI and as reduction in lean mass 
continues with time, this may also have an effect on ongoing BMD reduction and should be further 
evaluated.  
In terms of risk factors for reduced BMAD, our study demonstrated a positive association with 
increasing age consistent with previous study by Ruble et al. [28] There is increasing interest in the 
subject of frailty and premature aging in HSCT-TBI survivors that may have a direct and /or indirect 
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role in their bone health. It is not surprising that the presence of endocrine dysfunction was not 
associated with reduced BMAD in our study as all subjects with endocrinopathies were fully replaced. 
Similarly, it has been shown that BMAD was not decreased in children with thalassaemia after 
HSCT-TBI who were hormonally replete. [36] The lack of statistical associations between BMAD-
SDS and steroid dosage does not exclude the impact of steroids on BMD, and the outcome may 
merely be due to the high doses which have exceeded the threshold to demonstrate a linear dose 
dependant effect. The total steroid doses in the chemotherapy-group were in fact higher than the 
HSCT-TBI group as a number of high risk patients received HSCT before completion of the primary 
leukaemia protocol.  
The main strength of this study is the homogeneity of the cohort in terms of primary diagnosis. It is 
also the first study in the UK describing BMAD-SDS in HSCT-TBI survivors using multi-centred 
national reference data for our own population. However, the study was limited by the small numbers 
and cross-sectional design and fracture history may have been underestimated due to unrecognised 
vertebral collapse. The impact of the level and type of physical activity on bone density was not 
available in this study, but would be of great interest in future interventional studies. The treatment 
data of this study pre-dated the availability of electronic prescribing in our centre and there may be 
some imprecision in the dosages of total steroid exposure as additional doses given for other non-
treatment purposes e.g. anti-emetics were not all available. Future studies should have longitudinal 
and multicentre designs supported electronic medical records  
In conclusion, it is essential to correct BMD for size in patients with chronic disease affecting body 
composition and growth as in the case of HSCT-TBI survivors.  Size corrected BMD is reassuring in 
long term survivors of childhood leukaemia treated with HSCT-TBI who are on appropriate hormone 
replacement during adolescents and young adulthood. However, BMAD-SDS may decline with age 
faster in HSCT-TBI survivors than in the general population. Longitudinal studies to investigate 
changes in size-corrected BMD over time and to screen systematically for asymptomatic fractures 
particularly vertebral collapse are needed. A consistent approach to surveillance for fracture risk is 
important for the long term follow up of HSCT-TBI survivors. 
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size-correction over reported the number of patients with reduced BMD 
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